Suppressor of cytokine signaling (SOCS)-1 protein level was higher by 50% in post-MI than in Sham, though SOCS-3 levels were similar. These findings suggest that post-infarct remodeling disrupts cellular signaling from the EPO receptor to PI3K presumably by increased SOCS-1. However, in the remodeled myocardium, lack of PI3K/Akt activation by the EPO receptor appears to be compensated by a mechanism upstream of the guanylyl cyclase/mitoK ATP channel pathway to achieve EPO-induced protection.
Introduction
Erythropoietin (EPO) is an erythropoietic hormone that is produced primarily in juxtatubular cells of the kidney in response to hypoxia, and administration of recombinant human EPO has been used as a standard therapy for renal anemia for a decade. Recently, broad cytoprotective effects of EPO in various tissues have received attention (Maiese et al., 2005) . In studies using rat and rabbit hearts, recombinant human EPO as well as derivatives of EPO administered before or at the time of ischemia suppressed myocardial necrosis and apoptosis, ventricular dysfunction and ventricular remodeling after ischemia/reperfusion (Calvillo et al., 2003; Moon et al., 2003; Parsa et al., 2003; Lipsic et al., 2004; Wright et al., 2004; Fiordaliso et al., 2005) . Furthermore, these studies consistently showed that the phosphatidylinositol-3 kinase (PI3K)-Akt pathway plays a crucial role in the EPO-induced cardioprotection (Parsa et al., 2003; Cai and Semenza, 2004; Bullard et al., 2005; Hanlon et al., 2005; Rafiee et al., 2005) , though involvement of MAP kinase, protein kinase C (PKC) and mitochondrial ATP-sensitive K channel (mitoK ATP channel) has also been suggested (Shi et al., 2004; Bullard et al., 2005; Hanlon et al., 2005; Rafiee et al., 2005) . However, since normal myocardium was used in all these earlier studies to assess EPO-induced alteration in response to ischemia/reperfusion injury, it remains unknown whether EPO can afford cardioprotection to diseased hearts.
In the present study, we assessed whether EPO protects the myocardium in postinfarct hearts with ventricular remodeling. Myocardial infarction provokes remodeling of the heart over a period of several weeks or months, resulting in hypertrophy and interstitial fibrosis in the non-infarcted regions and dilation of the left ventricle. Intracellular signaling pathways responsible for the post-infarct remodeling potentially interact with intracellular signaling that induces cytoprotection. In fact, our previous studies have demonstrated that post-infarct ventricular remodeling made the myocardium refractory to ischemic preconditioning (PC) by disrupting signal transduction from the G-protein-coupled receptor to PKC-ε (Miki et al., 2000; Miki et al., 2003) . Since there are overlaps in signaling pathways provoked by PC and activated EPO receptors (Fisher, 2003; Smith et al., JPET#95745 process may also interfere with the mechanism of EPO-induced protection. Results of the present study suggest that post-infarct remodeling impairs the signaling pathway from activated EPO receptors to the PI3K/Akt pathway but that a compensatory mechanism upstream of guanylyl cyclase maintains the infarct size-limiting effect of EPO.
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balloon with a PE-50 polyethylene tube was inserted into the left ventricle and was connected to an SCK-580 transducer (Nihon-Kohden, Tokyo, Japan). Coronary flow was measured by timed collection of perfusate dripping from the heart.
Experimental protocol and measurement of infarct size
Protocol 1: In this protocol, hearts isolated 4 weeks after surgery were examined. After a 20-min stabilization period, all hearts were subjected to 25-min global ischemia and 2-hr reperfusion. Before global ischemia, each heart in the sham group was subjected to one of eight treatments: no pretreatment (control), infusion of 5 U/ml recombinant human EPO,
guanylyl cyclase inhibitor, EPO plus ODQ, 5-hydroxydecanoate (5-HD, 100 µM), a blocker of mitoK ATP channel, or EPO plus 5-HD. In the post-MI group, each heart was subjected to no pretreatment (control), EPO, EPO plus LY-294002, EPO plus wortmannin (100 nM), another PI3K inhibitor, EPO plus ODQ, or EPO plus 5-HD. EPO and each inhibitor were infused for 15 min commencing 15 min before the global ischemia.
Protocol 2: Since results of Protocol 1 showed that EPO-induced protective mechanisms were altered at 4 weeks after infarction (see Results), we examined whether such alteration in myocardial response to EPO develops during the earlier period after infarction. In this protocol, rat hearts were isolated at 2 weeks after coronary ligation and subjected to no pretreatment (control), infusion of EPO, or EPO plus LY-294002. Doses of EPO and LY-294002 and timings of infusion of these agents were the same as those in Protocol 1.
All hearts in this protocol were used for infarct size experiments.
After 2 hr of reperfusion, hearts were weighed, frozen, and cut into 1.5-mm-thick sections from apex to base. Infarcts in the heart slices were visualized by tetrazolium staining as previously reported (Miki et al., 2000; Tanno et al., 2000; Miki et al., 2003) .
Fresh infarcts, scar areas due to coronary ligation, and outlines of the ventricle were traced on a clear acetate sheet. The scarred infarct due to coronary ligation was transmural and JPET#95745 clearly distinguished from other areas of the left ventricle (Figure 1) , and the scar area was excluded from infarct size measurement.
Immunoblot assays
In this series of experiments, possible differences in cellular signaling after stimulation of the EPO receptor between post-MI hearts and sham-operated hearts were examined. Left ventricular biopsy samples (0.2~0.3 g) were taken from the isolated perfused hearts using sharp ophthalmology scissors at baseline, at 15 min after EPO infusion, or after 25-min ischemia/5-min reperfusion. In the post-MI group, tissues for immunoblotting were taken from the lateral ~ posterior wall since scarred infarct was located in the anterior wall ~ septum of the ventricle. Thus, tissues were sampled from the same regions in the sham group. We carefully excluded border zone tissues (i.e., apparently viable tissues within 1 mm next to scarred infarct) from tissue samples in the post-MI group. Since scarred regions were clearly distinguished from viable myocardium at 4 weeks after the coronary ligation, it was easy to obtain tissue samples exclusively from the non-infarcted areas in rat hearts. The tissues were frozen immediately after sampling in liquid nitrogen and stored at -80˚C till biochemical analysis. Frozen heart samples were homogenized in ice-cold buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 µg/ml leupeptin, 50 µg/ml phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail tablet (Complete, Roche Applied Science, Penzberg, Germany). The homogenate was centrifuged at 13,000 g for 15 min to obtain the supernatant. Protein concentration was determined using a Bio-Rad Protein Assay Kit 
Statistics
All data are presented as means±SEM. One-way analysis of variance (ANOVA) combined with the Student Newman-Keuls post hoc test was used to test for differences in heart weight, plasma EPO level and infarct size between treatment groups. Repeated measures ANOVA was used to test for differences in cardiac functions in any given group.
These statistical analyses were performed by using SigmaStat (SPSS, Chicago, IL). The difference was considered significant if the p value was less than 0.05. 
Results

Mortality and complete blood counts
A total of 150 rats were initially entered into this experiment. One rat in the sham group and 19 rats in the post-MI group died in their cages after surgery, probably due to atelectasis in the lungs and/or heart failure. Therefore, 130 surviving rats, 59 in the sham group and 71 in the post-MI group, contributed to the following analysis.
There were no significant differences in the numbers of white blood cells, red blood cells and platelets between the sham and post-MI groups (Table 1) . Plasma EPO level in the sham group was 14.5±1.1 mU/ml and the level was not changed at 4 weeks after MI. Mean blood pressures and heart rates in situ before isolation of the hearts at 4 weeks after surgery were also similar in the two groups. Heart weight, however, was significantly larger in the post-MI group than in the sham group, indicating ventricular remodeling after MI (Table 1) .
Data on cardiac functions
Protocol 1 Table 2 summarizes parameters of cardiac functions in the sham group. There were no significant differences in baseline heart rate and left ventricular developed pressure (LVDP) among the pretreatment groups, though coronary flow levels in hearts in the LY-294002 and EPO+5-HD groups were slightly higher than that in the control group.
Treatment with EPO and/or each blocker did not alter the hemodynamic parameters before the 25-min global ischemia. EPO treatment tended to improve LVDP after reperfusion, though the difference between LVDPs in the control and EPO-treated groups did not reach statistical significance. Coronary flow after reperfusion was decreased in all groups without significant inter-group differences.
In the post-MI hearts, baseline heart rate, LVDP, and coronary flow were comparable in pretreatment groups, though LVDP in the post-MI hearts was slightly lower than that in the sham-operated hearts (Table 3) were decreased in all pretreatment groups as in the sham group.
Protocol 2
Under baseline conditions, heart rate, LVDP, and coronary flow levels were 278±7 bpm, 103±7 mmHg, and 17.7±0.5 ml/min, respectively, in post-MI hearts entered this protocol. Alterations of these parameters after ischemia/reperfusion were similar to those observed in post-MI hearts in Protocol 1 (data not shown).
Infarct size data
Protocol 1
As shown in Table 4 , risk area sizes were comparable in the hearts in the sham and post-MI groups that were subjected to pretreatments. In the sham group, pretreatment with EPO significantly reduced infarct size as a percentage of risk area (%I/R) from 59.9±4.1% in controls to 36.2±4.2%. This EPO-induced protection was blocked by LY-294002, ODQ or 5-HD, although these blockers by themselves did not modify infarct size. In the post-MI group, there was no significant difference in the sizes of scarred infarct, ranging from 12 to 19% of the left ventricular mass. These sizes of scarred infarcts appear to be small but actually are underestimates of infarct sizes at the acute phase, since both thinning of scarred infarct and hypertrophy of non-infarct myocardium during the period of 4 weeks after infarction should have reduced volume percentages of the infarcted region. In the post-MI group, size of infarct after 25-min ischemia with no pretreatment (%I/R in control = 58.1±5.0%) was comparable with that in the sham group. Using separate groups of rats, we examined the effect of PC on infarct size in the post-MI group to confirm that post-infarct ventricular remodeling impairs the PC mechanism in rat hearts as we reported for rabbit hearts (Miki et al., 2000; Miki et al., 2003) .
As expected, PC with 2 cycles of 5-min ischemia/5-min reperfusion failed to limit infarct size (%I/R = 53.1±5.2%, n=3) in the post-MI hearts.
Protocol 2
Heart weight was 1.74±0.03 g in the rats 2 weeks after MI, which was only slightly smaller than the heart weight at 4 weeks after MI (Protocol 1), suggesting that substantial remodeling had occurred during a 2-week post-infarct period in the rats. EPO significantly reduced %I/R from 65.0±5.8% to 39.8±4.5%. This EPO-induced protection was not blocked by LY-294002 (Table 4) .
Immunoblot assays
EPO receptor protein was detected in the rat myocardium (Figure 2) , and its level was not altered by post-infarct ventricular remodeling or acute ischemia/reperfusion.
There was no significant difference in levels of total JAK2, total Akt and total eNOS in the study groups, and thus levels of phospho-JAK2, phospho-Akt and phospho-eNOS were normalized by their total protein levels. EPO increased the level of phospho-JAK2 in sham hearts, but the increase in phosphorylation levels of JAK2 by EPO was significantly attenuated in post-MI hearts (Figure 3 Figure 5A ). There was no significant difference between phospho-eNOS levels after ischemia/reperfusion in EPO-treated and untreated hearts ( Figure 5B ). SOCS-1 and SOCS-3 levels were higher by 54% and 12%, respectively, in the post-MI group than in the sham group, though only the difference in SOCS-1 levels was statistically significant (Figure 6 ). Ischemia/reperfusion with or without EPO pretreatment did not modify the levels of SOCS-1 and SOCS-3.
This article has not been copyedited and formatted. The final version may differ from this version. have been shown to negatively regulate JAK activation by EPO and other cytokines (Jegalian and Wu, 2002; Tan and Rabkin, 2005) . Indeed, activation of JAK2 by EPO was significantly attenuated in the remodeled myocardium (Figure 3) , in which SOCS-1 level was significantly elevated by 50% (Figure 6 ). The level of SOCS-3, which is known to be up-regulated by angiotensin II (Calegari et al., 2003; Calegari et al., 2005) , was slightly higher in the myocardium after 4 weeks of remodeling than in the control, but this difference was not statistically significant. The reason for SOCS-1 selective up-regulation in the present model of post-infarct remodeling remains to be investigated. Activation of the TNF-α receptor might have been involved in the SOCS-1 up-regulation, since the serum level of TNF-α and myocardial TNF-α mRNA level were shown to be elevated in rats after myocardial infarction (Ono et al., 1998; Berthonneche et al., 2004; Schulz et al., 2004; Tan and Rabkin, 2005) .
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suggested by a series of studies on mechanisms of PC against infarction (Krieg et al., 2004; Oldenburg et al., 2004; Costa et al., 2005; Krieg et al., 2005) . Krieg et al. (2004) showed that an Akt inhibitor and transfection of dominant negative Akt abolished NO-mediated activation of the mitoK ATP channel in response to PC triggered by bradykinin receptors. A recent study by Costa et al. (2005) demonstrated opening of the mitoK ATP channel in isolated mitochondria by addition of exogenous active PKG. Furthermore, it has been reported that EPO was capable of stimulating NO production in the rat hippocampus and endothelial cells (Beleslin-Cokic et al, 2004; Yamamoto et al., 2004) . Unfortunately, we could not demonstrate significant elevation of phospho-eNOS level by EPO, though there was a trend for increase by 10% in the present study. However, a larger difference may have been detected at later time points as it was in a study by Bullard et al. (2005) , who observed a 2-fold increase in phospho-eNOS induced by EPO in rat hearts 15 min after reperfusion, and the possibility of involvement of other NO-producing mechanisms also cannot be excluded. Nevertheless, we found for the first time that ODQ, a guanylyl cyclase inhibitor, abolished cardioprotection afforded by EPO similarly in both sham-operated and post-infarct hearts. Furthermore, this effect of ODQ was mimicked by 5-HD, a mitoK ATP channel blocker. Together with the results obtained by using PI3K inhibitors, these findings provide pharmacological evidence supporting the notion that PKG-mediated opening of the mitoK ATP channel is downstream of PI3K-Akt in EPO-induced cardioprotection and that compensation for the lack of Akt activation in post-infarct hearts is induced upstream of guanylyl cyclase.
It has been reported that EPO induced intracellular translocation of PKC-ε in buffer-perfused rabbit and rat hearts and that the infarct size-limiting effect of EPO was blocked by chelerythrine, a selective PKC inhibitor, indicating contribution of PKC to EPO-induced protection (Shi et al., 2004; Hanlon et al., 2005; Rafiee et al., 2005) . PKC-ε is thought to elicit opening of the mitoK ATP channel, leading to cardioprotection (Sato et al., 1998; Yellon and Downey, 2003) . However, our previous studies (Miki et al., 2000; Miki et al., 2003) anti-infarct tolerance in rabbit hearts remodeled after infarction. We confirmed lack of myocardial response to PC in post-infarct rat hearts also using infarct size as an end-point. Therefore, it is unlikely that PKC is involved in maintenance of myocardial response to EPO in post-infarct hearts.
In the present study, EPO was infused before ischemia and responses of signaling molecules during the pretreatment period were correlated with infarct tolerance of the myocardium. No significant difference was detected in the level of phospho-Akt upon reperfusion between the control group and EPO-pretreated group, though infarct size was significantly smaller in the EPO-treated group. However, efficacy of EPO for suppressing lethal reperfusion injury has been examined recently in several studies (Lipsic et al., 2004; Bullard et al., 2005; Hanlon et al., 2005) . Administration of EPO at the time of reperfusion resulted in infarct size limitation to an extent similar to that achieved by pretreatment with EPO in those studies (Lipsic et al., 2004; Hanlon et al., 2005) .
Furthermore, the importance of activation of signaling pathways at the time of reperfusion, including the PI3K-Akt pathway, for myocardial salvage has been suggested in cardioprotection afforded by preconditioning (Hausenloy and Yellon, 2004) . These findings suggest the possibility of clinical use of EPO for patients with acute myocardial infarction as an adjunct therapy to coronary reperfusion. Furthermore, a study by Namiuchi et al. (2005) showed that serum EPO level was an independent predictor for cumulative CK release in patients with first acute myocardial infarction, suggesting a cardioprotective role of endogenous EPO. In the present rat preparation, the role of endogenous EPO in protection against ischemic injury could not be assessed since plasma Representative Western blots and summarized data are presented for each group.
Values are expressed as arbitrary units (AU) and as means±SEM. *P<0.05 vs.
Sham. N=3~6. Blots for vinculin are loading controls.
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